|
T40541 |
α-Synuclein (61-75)
|
|
|
|
α-Synuclein (61-75) is a peptide fragment derived from the larger protein α-Synuclein. α-Synuclein is predominantly found in presynaptic nerve terminals and is considered to be a biomarker candidate for Parkinson's disea... |
|
T61644 |
α-Synuclein inhibitor 6
|
|
|
|
α-Synuclein inhibitor 6 (compound 3ge) is a highly effective and blood-brain barrier-permeable inhibitor that targets the aggregation of α-Synuclein (α-Syn). It exhibits a potent inhibitory activity, with an IC50 value o... |
|
T72314 |
α-Synuclein inhibitor 8
|
|
|
|
α-Synuclein inhibitor 8 effectively impedes α-Synuclein aggregation and disaggregation with an IC50 of 2.5 µM, demonstrating substantial reduction in neuronal inclusion formation, which contributes to reparative effects ... |
|
T80151 |
α-Synuclein 4554W
|
|
|
|
α-Synuclein 4554W, previously identified through intracellular library screening, is an inhibitor of α-Synuclein (aSyn) aggregation and its associated toxicity. This compound, comprising GIVNGVKA sequences, effectively r... |
|
T61920 |
α-Synuclein inhibitor 7
|
|
|
|
α- Synuclein inhibitor 7 (compound 3gf) is effective α- Synuclein ( α- Syn) aggregation inhibitor, IC50 is 1.95 μM, inhibition rate at 30μM was 85.8%. α- Synuclein inhibitor 7 has blood-brain barrier permeability. |
|
T62131 |
α-Synuclein inhibitor 5
|
|
|
|
α-Synuclein inhibitor 5 is a potent inhibitor of α-Synuclein (α-Syn) aggregation across the blood-brain barrier (IC50: 1.22 μM), with 94.3% inhibition at 30 μM. |
|
T78842 |
α-Synuclein inhibitor 9
|
|
|
|
α-Synuclein inhibitor 9 (Compound 20C) is a molecule that targets and binds to cavities within mature α-synuclein fibrils, diminishing their β-sheet content. It effectively inhibits the aggregation of A53T α-synuclein an... |
|
T61404 |
α-Synuclein inhibitor 3
|
|
|
|
α-Synuclein inhibitor 3 (Compound 7g) is a potent inhibitor of α-synuclein (α -Syn) aggregation. It has potential applications in Parkinson's disease research [1]. |
|
T61611 |
α-Synuclein inhibitor 4
|
|
|
|
α-Synuclein inhibitor 4 (compound 3gh) is a highly effective and blood-brain barrier-permeable inhibitor of α-Synuclein aggregation. It displays potent activity, with an IC50 value of 0.98 μM, and exhibits a remarkable i... |
|
T9722 |
YTX-465
|
|
Stearoyl-CoA Desaturase (SCD)
|
|
YTX-465 is an inhibitor of both stearoyl-CoA desaturase(IC50s = 39 nM) and Ole1 (IC50s = 30.4 μM). |
|
T81031 |
Tau protein/α-synuclein-IN-1
|
|
|
|
Tau protein/α-synuclein-IN-1 is a dual inhibitor that not only impedes tau protein and α-synuclein but also reduces the development of α-syn inclusions in M17D neuroblastoma cells, making it a useful agent in the study o... |
|
T62226 |
Dyrk1A/α-synuclein-IN-2
|
|
|
|
Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual inhibitor of Dyrk1A and α-synuclein aggregation that acts on α-synuclein (IC50: 7.8 μM). Dyrk1A/α-synuclein-IN-2 has a high predictive CNS permeability and neuroprotective... |
|
T76199 |
α-Synuclein (61-75) (TFA)
|
|
|
|
α-Synuclein (61-75) TFA is a fragment (residues 61-75) of the abundant neuronal protein α-Synuclein, which is predominantly located in presynaptic nerve terminals. α-Synuclein serves as a potential biomarker for Parkinso... |
|
T62096 |
Dyrk1A/α-synuclein-IN-1
|
|
|
|
Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual inhibitor of Dyrk1A (IC50: 177 nM) and α-synuclein aggregation (IC50: 10.5 μM). CNS permeability and neuroprotective activity. |
|
T78629 |
PROTAC α-synuclein degrader 3
|
|
PROTACs
|
|
PROTAC α-synuclein degrader 3 (compound 5) serves as a potent and selective agent for degrading α-synuclein and is utilized in Parkinson's disease research [1]. |
|
T80118 |
α-Synuclein (61-95) (human)
|
|
|
|
α-Synuclein (61-95) (human) constitutes the hydrophobic core of α-synuclein and is implicated in inducing neuronal cell death. This segment is utilized in the study of neurodegenerative conditions such as Alzheimer's dis... |
|
T79250 |
PROTAC α-synuclein degrader 5
|
|
PROTACs
|
|
PROTAC α-synuclein degrader 5 is a highly selective (PROTAC) compound that targets and degrades α-synuclein aggregates, exhibiting an DC50 value of 7.51 μM and achieving a maximum degradation rate (Dmax) of 89%. The comp... |
|
T4659 |
ELN484228
|
|
Others
|
|
ELN484228 is a α-synuclein blocker. α-synuclein is a key protein in Parkinson’s disease. |
|
T62304 |
Minzasolmin
|
(R)-NPT200-11,UCB0599,DLX-313 |
Others
|
|
Minzasolmin(DLX-313) is an alpha-synuclein misfolding inhibitor for the study of Parkinson's disease. |
|
T13048 |
SynuClean-D
|
SC-D |
Others
|
|
SynuClean-D (SC-D) is an α-synuclein aggregation inhibitor preventing fibril propagation, disrupting mature amyloid fibrils, and abolishing the degeneration of dopaminergic neurons in an animal model of Parkinson’s disea... |
|
T72420 |
MTK458
|
Mitophagy activator 1,EP-0035985 |
PTEN
|
|
MTK458 (EP-0035985) is an orally active and brain-permeable PINK1 activator that promotes pathological clearance of alpha-synuclein and reduces pUb in a PFF inoculation model.MTK458 induces pathological alpha-synuclein c... |
|
T76861 |
Cinpanemab
|
BIIB054 |
Others
|
|
Cinpanemab (BIIB054) is a novel human monoclonal antibody with affinity for alpha-synuclein residues 1-10. Cinpanemab can be used to study Parkinson's disease and related diseases. |
|
T63321 |
20S Proteasome activator 1
|
|
Proteasome
|
|
20S Proteasome activator 1 is a 20S proteasome activator with IC50 of 0.3 μM for trypsin-like sites, 0.7 μM for chymotrypsin-like sites and 1.8 μM for caspase sites. 20S Proteasome activator 1 prevents the accumulation o... |
|
T83726 |
Tat-βsyn-degron TFA
|
|
|
|
Tat-βsyn-degron, an α-synuclein knockdown peptide, integrates three domains: the HIV-1 Tat plasma membrane transduction domain, an α-synuclein binding domain (βsyn) representing amino acids 36-45 of β-synuclein, and a pr... |
|
T13049 |
Synucleozid
|
NSC 377363 |
Others
|
|
Synucleozid is a potent the SNCA mRNA inhibitor that encodes α-synuclein protein (IC50=1.5 μM), has the potential for the investigation of Parkinson’s disease. |
|
T76889 |
Prasinezumab
|
|
|
|
Prasinezumab (PRX 002), a humanized IgG1 monoclonal antibody targeting aggregated α-synuclein, shows promise for Parkinson's disease research [1]. |
|
T71174 |
PBT434 HBr
|
|
|
|
PBT434 is a novel, brain-penetrant, small molecule inhibitor of α-synuclein aggregation. In transgenic animal models of Parkinson disease (A53T) and MSA (PLP-α-Syn), PBT434 reduced α-synuclein aggregation, preserved neur... |
|
T74974 |
SQ-3
|
|
|
|
SQ-3, a quinoline analogue, demonstrates moderate selectivity towards α-synuclein aggregates (α-syn aggregates) (K i = 39.3 nM) over β-amyloid (Aβ) aggregates (K i = 230 nM). [18 F]SQ-3 exhibits foundational characterist... |
|
T68763 |
PQQ-TME
|
|
|
|
PQQ-TME exhibits greater inhibitory activity against fibrillation of α-synuclein, Aβ1-42, and prion protein than PQQ. PQQ-TME also has twice the BBB permeability than PQQ in vitro. |
|
T13049L |
Synucleozid hydrochloride (502139-01-7 free base)
|
Synucleozid hydrochloride,NSC 377363 hydrochloride |
Others
|
|
Synucleozid hydrochloride is a potent the SNCA mRNA inhibitor that encodes α-synuclein protein (IC50=1.5 μM), has the potential for the investigation of Parkinson’s disease. |
|
T72280 |
PBT434 methanesulfonate
|
|
|
|
PBT434 methanesulfonate is an orally active, potent α-synuclein aggregation inhibitor with the ability to cross the blood-brain barrier. Acting as an iron chelator, it modulates transcellular iron trafficking, inhibits i... |
|
T83875 |
HUP-55
|
|
|
|
HUP-55 is a prolyl endopeptidase inhibitor with an IC50 of 5 nM, shown to mitigate α-synuclein dimerization in Neuro2a cells, stimulate autophagy in HEK293 cells, and lower hydrogen peroxide-evoked reactive oxygen specie... |
|
T70941 |
CLR01 sodium
|
|
|
|
CLR01 is a molecular tweezer. CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy. CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro ... |
|
T83328 |
4A7C-301
|
|
|
|
4A7C-301, a Nurr1 agonist, exhibits potent neuroprotective effects in vitro and markedly mitigates neuropathological abnormalities while enhancing motor and olfactory functions in male mouse models with AAV2-mediated α-s... |
|
T74770 |
D-685
|
|
|
|
D-685, a prodrug of D-520, demonstrates enhanced anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model compared to its parent compound D-520. It effectively reduces the buildup of human α-syn... |
|
T78171 |
QR-0217
|
|
|
|
QR-0217 is a potent inhibitor of both Aβ1-40 and α-synuclein aggregation, exhibiting an IC50 of 7.5 µM for Aβ1-40. Additionally, QR-0217 has been shown to alleviate memory impairments attributed to Aβ neurotoxicity [1]. |
|
T37533 |
DOPAL
|
|
|
|
DOPAL is an aldehyde product of the oxidative deamination of dopamine by monoamine oxidase.[1] It can be further oxidized to 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenase (ALDH) and, to a lesser extent... |
|
T36903 |
Rasagiline-13C3 (mesylate)
|
Rasagiline-13C3 (mesylate) |
|
|
Rasagiline-13C3is intended for use as an internal standard for the quantification of rasagiline by GC- or LC-MS. Rasagiline is an inhibitor of monoamine oxidase B (MAO-B; IC50= 4.43 nM for the rat brain enzyme).1It is se... |
|
T83894 |
4A7C-301-Nurr1 Agonist
|
4A7C-301-Nuclear Receptor-Related 1 |
|
|
The compound 4A7C-301-Nurr1 agonist is a specific agonist for the nuclear receptor-related 1 (Nurr1). By binding to the Nurr1 ligand-binding domain with an IC50 value of 48.22 nM, it enhances the transcriptional activity... |
